Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 1, 2009, Pages 229-234

  Boyd, Lauren Becnel ^a   Maynard, Merry J ^a   Morgan Linnell, Sonia K ^a   Horton, Lori Banks ^a   Sucgang, Richard ^a   Hamill, Richard J ^a,b   Jimenez, Javier Rojo ^c   Versalovic, James ^a   Steffen, David ^a   Zechiedrich, Lynn ^a,d  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Rice University   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; NORFLOXACIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG STRUCTURE; ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; NORFLOXACIN; OFLOXACIN; UNITED STATES;

EID: 59749106535     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00722-08     Document Type: Article

References (30)

1. Ball, P. 1994. Bacterial resistance to fluorquinolones: lessons to be learned. Infection 22:S140-S147.
2. Becnel Boyd, L., R. L. Atmar, G. L. Randall, R. J. Hamill, D. Steffen, and L. Zechiedrich. 2008. Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect. Dis. 8:4.
3. Dalhoff, A. 2001. Comparative in vitro and in vivo activity of the C-8 methoxy quinolone moxifloxacin and the C-8 chlorine quinolone BAY y 3118. Clin. Infect. Dis. 32:S16-22.
4. Dong, Y., C. Xu, X. Zhao, J. Domagala, and K. Drlica. 1998. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob. Agents Chemother. 42:2978-2984.
5. Dong, Y., X. Zhao, J. Domagala, and K. Drlica. 1999. Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus. Antimicrob. Agents Chemother. 43:1756-1758.
6. Drlica, K., M. Malik, R. J. Kerns, and X. Zhao. 2008. Quinolone-mediated bacterial death. Antimicrob. Agents Chemother. 52:385-392.
7. Froelich-Ammon, S. J., and N. Osheroff. 1995. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. J. Biol. Chem. 270:21429-21432.
8. Fung-Tomc, J., B. Kolek, and D. P. Bonner. 1993. Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 37:1289-1296.
9. Gillespie, S. H., S. Basu, A. L. Dickens, D. M. O'Sullivan, and T. D. McHugh. 2005. Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J. Antimicrob. Chemother. 56:344-348.
10. Heisig, P., and B. Wiedemann. 1991. Use of a broad host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria. Antimicrob. Agents Chemother. 35:2031-2036.
11. Kitamura, A., K. Hoshino, Y. Kimura, I. Hayakawa, and K. Sato. 1995. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1467-1471.
12. Komp Lindgren, P., A. Karlsson, and D. Hughes. 2003. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob. Agents Chemother. 47:3222-3232.
13. Lu, T., X. Zhao, X. Li, A. Drlica-Wagner, J. Y. Wang, J. Domagala, and K. Drlica. 2001. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2703-2709.
14. Luo, N., S. Pereira, O. Sahin, J. Lin, S. Huang, L. Michel, and Q. Zhang. 2005. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc. Natl. Acad. Sci. USA 102:541-546.
15. Matic, I., M. Radman, F. Taddei, B. Picard, C. Doit, E. Bingen, E. Denamur, and J. Elion. 1997. Highly variable mutation rates in commensal and pathogenic Escherichia coli. Science 277:1833-1834.
16. Morgan-Linnell, S. K., L. Becnel Boyd, D. Steffen, and L. Zechiedrich. 2009. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 53:235-241.
17. Morgan-Linnell, S. K., and L. Zechiedrich. 2007. Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 51:4205-4208.
18. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 6th ed., M7-A6. 23. NCCLS, Wayne, PA.
19. NCCLS. 2003. MIC testing supplemental tables, M100-S13 (M7). NCCLS, Wayne, PA.
20. Olofsson, S. K., L. L. Marcusson, A. Stromback, D. Hughes, and O. Cars. 2007. Dose-related selection of fluoroquinolone-resistant Escherichia coli. J. Antimicrob. Chemother. 60:795-801.
21. Périchon, B., P. Courvalin, and M. Galimand. 2007. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob. Agents Chemother. 51:2464-2469.
22. Rayssiguier, C., D. S. Thaler, and M. Radman. 1989. The barrier to recombination between Escherichia coli and Salmonella typhimurium is disrupted in mismatch-repair mutants. Nature 342:396-401.
23. Robicsek, A., J. Strahilevitz, G. A. Jacoby, M. Macielag, D. Abbanat, C. H. Park, K. Bush, and D. C. Hooper. 2006. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat. Med. 12:83-88.
24. Rolston, K. V., I. Vaziri, S. Frisbee-Hume, H. Streeter, and B. LeBlanc. 2004. In vitro antimicrobial activity of gatifloxacin compared with other quinolones against clinical isolates from cancer patients. Chemotherapy 50:214-220.
25. Tanabe, K., T. Kondo, Y. Onodera, and M. Furusawa. 1999. A conspicuous adaptability to antibiotics in the Escherichia coli mutator strain, dnaQ49. FEMS Microbiol. Lett. 176:191-196.
26. Wang, M., J. H. Tran, G. A. Jacoby, Y. Zhang, F. Wang, and D. C. Hooper. 2003. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob. Agents Chemother. 47:2242-2248.
27. Yamane, K., J. I. Wachino, S. Suzuki, K. Kimura, N. Shibata, H. Kato, K. Shibayama, T. Konda, and Y. Arakawa. 2007. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate. Antimicrob. Agents Chemother. 51:3354-3360.
28. Yang, S., S. Clayton Rahmati, and E. L. Zechiedrich. 2003. Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli. J. Antimicrob. Chemother. 51:545-556.
29. Zhao, X., and K. Drlica. 2001. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33:S147-S156.
30. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996.